Menu Search
Equities

Redwood Pharma AB

9JV0:FRA

Redwood Pharma AB

Actions
  • Price (EUR)0.073
  • Today's Change0.000 / -0.27%
  • Shares traded-1.00
  • 1 Year change-96.99%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 14:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Redwood Pharma AB is a Sweden-based company, which is primarily focused on pharmaceutical industry. The Company develops IntelliGel, a patented hydrogel drug delivery platform technology. IntelliGel is a patented supramolecular smart drug delivery system with an ability to dissolve water-insoluble and sparingly soluble drugs, or disperse, suspend and stabilize otherwise insoluble drugs. It is an odor-free, clear and transparent hydrogel with low solid content, and forms an invisible patch when applied to a surface. The Company’s development product is focused on treatment of chronic Dry Eye Disease (DED) in post-menopausal women. It is based on a naturally occurring, endogenous molecule found in the body.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-13.60m
  • Incorporated2012
  • Employees1.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.